NPM1 and acute myeloid leukemia: In 2017, the imidazoquinoxaline derivative EAPB0503 was found as a NPM1c+ inhibition active in AML and reduced cell growth in the NPM1c+ OCI-AML3 cell line and patient samples, but not in wild-type NPM1 THP-1 and MOLM-13 cell lines or wild-type NPM1 patient samples.